Rasonque Sales Reach $198 Million in Five Weeks

Revolution Medicines reported the pancreatic cancer drug's early sales after its U.S. approval, with more than 5,000 patients treated.

Updated on Nov. 5, 2026 in Cancer

Clear glass flasks of pale amber liquid on a brushed steel laboratory bench in soft window light. — Revolution Medicines reported $198 million in Rasonque sales in five weeks after FDA approval, with more than 5,000 patients treated. AI Illustration. Upload story photo >

Revolution Medicines reported that Rasonque, its pancreatic cancer drug, generated $198 million in sales in the five weeks after the U.S. Food and Drug Administration approved it as a pan-RAS inhibitor. The company said more than 5,000 patients have been treated with the drug.

Why it matters

The early sales figure is nearly double the most bullish investor estimates held before the company's third-quarter earnings announcement, prompting investors to re-evaluate their forecasts. The strong launch signals rapid uptake of a new targeted option for pancreatic cancer patients in the United States.

The figures come from Revolution Medicines' own earnings call disclosure rather than an independent audit. The company has not indicated how sales will trend beyond the initial five-week launch period.

The players

Revolution Medicines

Revolution Medicines is a biopharmaceutical company focused on developing targeted therapies against RAS-driven cancers, the developer of Rasonque.

Anthony Mancini

Anthony Mancini is the Chief Commercial Officer of Revolution Medicines, who described the U.S. launch of Rasonque as off to a strong start.

The details

Revolution Medicines disclosed the sales and patient totals on its earnings call Wednesday evening. Chief Commercial Officer Anthony Mancini described the U.S. launch as off to a strong start.

Five weeks after U.S. approval, Rasonque had reached $198 million in sales.
Revolution Medicines announced the sales and patient totals on its earnings call on November 4, 2026.

Roadmap

Rasonque is a pan-RAS inhibitor, a class of drugs aimed at the RAS protein family that drives many difficult-to-treat cancers. Its U.S. approval marks one of the first commercial products targeting RAS in pancreatic cancer, a disease with historically limited treatment options.

For patients with pancreatic cancer, the drug's rapid uptake suggests it is becoming an available treatment option. Patients and families should discuss with their oncologists whether a pan-RAS inhibitor is appropriate for their specific condition.

The takeaway

The rapid early uptake of Rasonque shows that targeted RAS-directed therapies are moving quickly from approval into routine clinical use. Patients interested in new options should review them with their treating physicians.